PARP inhibitorsTriple-negative breast cancerDespite recent advances in the clinical evaluation of various poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer (TNBC) patients, data defining potential anti-tumor mechanisms beyond PARP...
Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015; 13:188.Livraghi L, Garber JE (2015) PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med 13:188 Central...
tated Breast Cancer The Promise of PARP Inhibitors for BRCA-Mutated Breast CancerThe Promise of PARP Inhibitors for BRCA-Mutated Breast CancerTony Hagen
Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms Aditi Jain Alan Barge Christopher N. Parris ReviewsOpen Access21 Nov 2024Oncogene P: 1-15 Comparative evaluation of collagen modifications in breast cancer in human and canine carcino...
Updates on Targeted Therapy for Triple-Negative Breast Cancer (TNBC) Triple-negative breast cancerTNBCImmune checkpoint inhibitionTargeted therapyPARP inhibitorsAntibody-drug conjugatePurpose of Review We will provide a brief update... ZS Noor,A Master - 《Current Breast Cancer Reports》 被引量: 0发表...
PARP inhibitors in the management of breast cancer: current data and future prospects Poly(ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage repair. Inhibition of PARPs is a promising strategy for targeting cancers with defec... L Livraghi,JE Garber - 《Bmc Medicine》 被引量:...
Poly(ADP㏑ibose) Polymerase (PARP) Inhibitors for locally advanced or metastatic breast cancer Cohrane Database of Systematic ReviewsMustafaKhasraw, Sujata MPatil, Tiffany ATraina, Mark ERobson, MustafaKhasraw. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for locally advanced or metastatic breast ...
signaling, interleukin (IL)-12 pathway, and IL-7 pathway. Thus, the IM subtype is highly similar to medullary carcinoma of the breast [16]. It is recommended to use PD1, PDL1, CTLA-4, and other immune checkpoint inhibitors for the treatment of patients with IM subtype breast cancer [14...
专利名称：TREATMENT OF BREAST CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTI-TUMOR AGENTS 发明人：SHERMAN, Barry, M.,BRADLEY,Charles,OSSOVSKAYA, Valeria, S.申请号：US2008083147 申请日：20081111 公开号：WO09/064738P1 公开日：20090522 专利内容由知识产权出版社提供 摘要：In one ...
Also, GDP-M was shown in the lab to be capable of empowering a class of targeted agents for breast cancer treatment called PARP inhibitors. The new finding points to a clinical strategy combining GDP-M with other DNA repair-targeted therapy, said the researchers.■...